In the heart of Pune, Dr. Bhagyashree Patil's Rise N Shine Biotech is transforming rural economies through cutting-edge science. This thriving hub mainly employs local women, equipping them with ...
Indoco Remedies has secured final USFDA approval for its generic Lacosamide oral solution, a bioequivalent of Vimpat, enabling the company to market this essential epilepsy treatment in the US from ...
Indoco Remedies receives USFDA approval to market generic Lacosamide oral solution for epilepsy treatment. Manufactured in Goa facility.
Mumbai: Indoco Remedies Ltd. has received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated ...
Indoco Remedies receives US FDA final approval for its ANDA for lacosamide oral solution USP, 10 mg/mL: Our Bureau, Mumbai Friday, January 30, 2026, 14:30 Hrs [IST] Indoco Remedie ...
Indoco Remedies announced final approval of the Company's Abbreviated New Drug Application (ANDA) for Lacosamide Oral Solution USP, 10 mg/mL, to market, a generic equivalent to the reference listed ...
Lacosamide Oral Solution is used in the treatment of partial onset seizures and primary generalised tonic-clonic seizures in adults and children aged four years and above with epilepsy.
Opinion
The Daily Pour on MSNOpinion
Crisis Ahead for Medical Patients? Hemp THC Ban Threatens Critical Treatments
Despite significant advancement in the normalization of cannabis compared to five or 10 years ago, preconceptions about who consumes hemp-derived products remain extremely common. The stereotype skews ...
15don MSN
'He saved my life' - Northumberland hero called ambulance for man having seizures 1,000 miles away
Northumberland musician Guy Stoker helped get lifesaving support to a Danish man he was chatting to on Instagram ...
New Delhi, Jan 30 (PTI) Indoco Remedies Ltd on Friday said it has received approval from the US health regulator to market its generic version of Lacosamide oral solution used in the treatment of ...
Up to 189 health conditions could potentially affect your ability to drive, with seven specific conditions that must be declared to the DVLA ...
Xenon Pharmaceuticals Inc. Phase 3 X-TOLE2 topline data for azetukalner in FOS expected March 2026 followed by anticipated NDA submission in H2 2026. Five additional Phase 3 azetu ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results